Xponance Inc. Sells 414 Shares of Moderna, Inc. (NASDAQ:MRNA)

Xponance Inc. reduced its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 0.9% in the fourth quarter, HoldingsChannel reports. The firm owned 44,770 shares of the company’s stock after selling 414 shares during the quarter. Xponance Inc.’s holdings in Moderna were worth $1,862,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also made changes to their positions in MRNA. abrdn plc grew its stake in shares of Moderna by 28.1% during the 4th quarter. abrdn plc now owns 315,912 shares of the company’s stock valued at $12,842,000 after acquiring an additional 69,360 shares during the period. Y Intercept Hong Kong Ltd grew its stake in shares of Moderna by 30.9% during the 3rd quarter. Y Intercept Hong Kong Ltd now owns 101,159 shares of the company’s stock valued at $6,760,000 after acquiring an additional 23,881 shares during the period. Spire Wealth Management grew its stake in shares of Moderna by 2,150.4% during the 4th quarter. Spire Wealth Management now owns 23,224 shares of the company’s stock valued at $966,000 after acquiring an additional 22,192 shares during the period. Citigroup Inc. grew its stake in shares of Moderna by 30.5% during the 3rd quarter. Citigroup Inc. now owns 591,910 shares of the company’s stock valued at $39,557,000 after acquiring an additional 138,378 shares during the period. Finally, Geode Capital Management LLC boosted its stake in Moderna by 2.6% in the 3rd quarter. Geode Capital Management LLC now owns 7,069,580 shares of the company’s stock worth $470,670,000 after purchasing an additional 178,115 shares during the period. 75.33% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on MRNA. Barclays downgraded Moderna from an “overweight” rating to an “equal weight” rating and dropped their price target for the stock from $111.00 to $45.00 in a research note on Tuesday, February 18th. Evercore ISI set a $50.00 price target on Moderna in a research note on Friday, February 14th. UBS Group dropped their price target on Moderna from $96.00 to $78.00 and set a “buy” rating for the company in a research note on Wednesday, February 19th. Leerink Partners dropped their price target on Moderna from $31.00 to $27.00 and set an “underweight” rating for the company in a research note on Thursday, January 16th. Finally, Morgan Stanley dropped their price target on Moderna from $70.00 to $38.00 and set an “equal weight” rating for the company in a research note on Wednesday, January 15th. Four equities research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $59.00.

Moderna Stock Performance

NASDAQ:MRNA opened at $32.66 on Friday. The stock’s fifty day moving average is $34.91 and its 200 day moving average is $45.86. Moderna, Inc. has a fifty-two week low of $29.25 and a fifty-two week high of $170.47. The firm has a market capitalization of $12.60 billion, a PE ratio of -3.52 and a beta of 1.86.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.